

(+)-*epi*- α -Bisbolol Is the Wound-Healing Principle of *Peperomia galioides*: Investigation of the in Vivo Wound-Healing Activity of Related Terpenoids

León F. Villegas,[†] Ana Marçalo,[‡] Jennifer Martin,[‡] Irma D. Fernández,[†] Holger Maldonado,[§] Abraham J. Vaisberg,^{⊥,∇} and Gerald B. Hammond^{*,†,∇}


Department of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, Departamento de Ciencias Fisiológicas, Universidad Peruana Cayetano Heredia, Apto. Postal 4314, Lima 100, Perú, Departamento de Química, Universidad Peruana Cayetano Heredia, Apto. Postal 4314, Lima 100, Perú, and Laboratorios de Investigación y Desarrollo de Ciencia y Tecnología, y Departamento de Microbiología, Universidad Peruana Cayetano Heredia, Apto. Postal 4314, Lima 100, Perú

Received June 15, 2001

Bioassay-guided investigation of the ethanol extract of *Peperomia galioides* using a tensile strength method in mice as a monitor led to the isolation of *epi*- α -bisabolol (**1**) (ED₅₀ 155 μ g/mL). An in vivo healing study of selected commercially available monoterpenoids yielded two bioactive compounds, α -bisabolol (**2**) and α -terpineol (**3**) (ED₅₀ of 228 and 240 mg/g mouse, respectively).

Impaired wound-healing is a significant source of morbidity and may result in severe health-related complications, such as infections and tissue necrosis.¹ Impaired wound-healing is associated with several conditions such as diabetes, immunosuppression, obesity, and malnutrition. The scientific study of wound-healing (cicatrizant) plants, which can promote or aid in the normal wound-healing process, could help patients whose wounds do not scar easily. Notwithstanding these medical benefits, an in-depth study of wound-healing agents may also expose a potential link between acute injury and the treatment of proliferative disorders.² Our initial foray in the field of natural cicatrizants was the study of the tree sap from *Croton lechleri* L. (Euphorbiaceae) ("Sangre de Grado"), known in folk medicine for its healing action. This investigation resulted in the isolation of taspine, the wound-healing principle in the sap.³ This alkaloid accelerates the healing process, presumably, by increasing the migration of fibroblasts to the wounded area during the early stages of cicatrization.⁴ Our group's focus on cicatrizant agents from natural sources is part of an interdisciplinary, systematic, and targeted study of traditional Peruvian medicinal plants.⁵ In the past decade, the number of publications related to *C. lechleri* and other natural wound-healing agents has increased substantially,⁶ including our recent survey of Peruvian plant species with potential cicatrizant action.⁷ One such plant, *Peperomia galioides* H.B.K. (Piperaceae) ("Congona"), is a succulent herb, used in traditional medicine as a compress—made from the crushed plant except the roots—that is applied on cuts and wounds to accelerate healing. The juice is swallowed to treat gastric ulcers. We found that the ethanol extract of *P. galioides* exhibited significant wound-healing activity in vivo, without any increase in the proliferation of 3T3 mouse fibroblasts and with no detectable mutagenicity.⁸ Cavé and co-workers have published the only previous phytochemical investigation of *P. galioides*. They isolated, from the petroleum ether

extract, a prenylated quinone with in vitro antiparasitic activity.⁹ We report now the isolation of (+)-*epi*- α -bisabolol, **1**, responsible for the in vivo cicatrizant activity of *P. galioides*, and also provide a preliminary account of our investigation on the wound-healing activity of terpenols **2–5**.



The ethanol extract of *P. galioides* was partitioned between water and dichloromethane, resulting in an enhanced activity of the latter fraction. Further partitioning (90% aqueous methanol/hexane) concentrated the bioactivity in the hexane layer. Chromatographic purification (radial chromatography and HPLC) of the hexane extract led to the isolation of (+)-*epi*- α -bisabolol (**1**). The optical rotation and NMR spectra of **1** were identical to those reported in the literature,^{10–13} including the characteristic C-1' methyl singlet (δ 1.14 ppm in CDCl₃). Because the (–)-enantiomer is known as (–)-anymol,¹¹ some authors¹² prefer to use the name (+)-anymol when referring to **1**. Other components of *P. galioides*, isolated during the bioassay-guided fractionation procedure, included the methyl ester of grifolic acid,¹⁴ grifolin,¹⁴ and viridiflorol.¹⁵ The cicatrizant activity (ED₅₀) of **1**, determined using a tensile strength method,⁸ and its cytotoxicity against 3T3 mouse fibroblasts (GI₅₀)³ are shown in Table 1.

With an interest in seeking readily available sources of cicatrizant agents, as well as to begin to understand the structural features needed for their wound-healing activity, we examined the in vivo healing action of selected and commercially available terpenols whose carbon skeletons

* To whom correspondence should be addressed. Tel: (508) 999-8865. Fax: (312) 910-6918. E-mail: ghammond@umassd.edu.

[†] Departamento de Ciencias Fisiológicas, Universidad Peruana Cayetano Heredia.

[‡] University of Massachusetts Dartmouth.

[§] Departamento de Química, Universidad Peruana Cayetano Heredia.

[⊥] Laboratorios de Investigación y Desarrollo y Departamento de Microbiología, Universidad Peruana Cayetano Heredia.

[∇] G.B.H. and A.J.V. share senior coauthorship.

Table 1. Wound Healing Activity and Cytotoxicity for Compounds **1–3** Expressed as ED₅₀^a and GI₅₀, Respectively

	(+)- <i>epi</i> - α -bisabolol (1)	α -bisabolol racemate (2)	α -terpineol racemate (3)
ED ₅₀ (μ g/g mouse)	155	228	240
GI ₅₀ value against 3T3 cells (μ g/mL)	8.0	84	17

^aED₅₀ values were calculated from the regression equation obtained from a dose–response analysis. Statistical analysis using the Student's *t*-test showed that the difference between the control group and the treated group of mice was significant ($p < 0.05$). The control experiments utilized mice who received only the solvent in which the compound was diluted.

bear some resemblance to **1**, namely, α -bisabolol (**2**), α -terpineol (**3**), *trans*-nerolidol (**4**), and *trans,trans*-farnesol (**5**). α -Bisabolol (**2**), the epimer of **1**, is a common plant secondary metabolite. Its (–)-enantiomer is the main constituent of chamomile (*Matricaria chamomilla* L.) and has been shown to shorten the healing time in cutaneous burns of guinea pigs exposed to UV light.¹⁶ In terms of its structure, **3** displays a skeletal arrangement similar to **1**, minus the isoprene chain, while **4** is an acyclic isomer of **1** bearing a tertiary alcohol, albeit on a different location. On the other hand, **5**, another acyclic isomer of **2**, features a primary alcohol instead of the tertiary hydroxyl group.

Our results indicate that whereas both **2** and **3** showed significant in vivo cicatrizing activity (Table 1), the acyclic isomers **4** and **5** were inactive; that is, their wound breaking strength data were lower or similar to the control experiments. For comparison, the ED₅₀ of taspine was 15 μ g/g mouse, but its cytotoxicity was much greater than **1–3**.¹⁷ Thus, compared with taspine, terpenols **1–3** are less potent, but also much less cytotoxic, and more accessible in terms of their chemical synthesis. For example, whereas the total synthesis of taspine has only recently been achieved,¹⁸ compounds **2** and **3** are commercially available, and **1** has been prepared using various synthetic routes.^{10,19} One might speculate that the 1-methylcyclohexene moiety and the tertiary hydroxyl group on C-1' are important structural fixtures for the wound-healing enhancement observed in **1–3**, while the isoprene side chain and the stereochemistry on C-4 may be less relevant for wound-healing activity.²⁰ Migration of fibroblasts is an important parameter in the cicatrization process (vide supra), since disturbance in the arrangement of a tissue, by wounding, normally initiates migration of the surrounding cells to the wounded area. We tested the effect of **1** on cell migration by inflicting a "wound" on a cell monolayer, using our published procedure,³ but found that this compound did not have a significant effect on increasing cell migration.

Experimental Section

General Experimental Procedures. Commercially available samples of α -bisabolol (**2**) (Fluka 14462), *trans*-nerolidol (Aldrich 33,525-8) (**3**), α -terpineol (Aldrich 43,262-8) (**4**), and *trans,trans*-farnesol (Aldrich 27,754-1) (**5**) were purchased and used without further purification. Optical rotations were obtained on a Perkin-Elmer model 241 polarimeter. ¹H and ¹³C NMR data were measured in CDCl₃ at 300 and 75 MHz, respectively (Bruker AC 300 FT-NMR), referenced against internal tetramethylsilane at δ 0.0 ppm. *J* values are given in Hz. Low-resolution EIMS were recorded on a HP 5890/5970 GCMS. HRMS data were obtained at the Midwest Center for Mass Spectrometry, University of Nebraska–Lincoln. Analytical TLC was performed using Macherey-Nagel Polygram Sil G/UV₂₅₄ precoated plates. Column chromatography utilized Si gel, 63–200 μ m (Scientific Adsorbents, Inc.). Radial chromatography was performed on 1 or 2 mm Si gel coated circular

glass plates using a Chromatotron apparatus. High-performance liquid chromatography was carried out using a Rainin gradient HPLC system (Dynamax SD-200 pumps) with UV-M multiwavelength detector.

Plant Material. *Peperomia galioides* H.B.K. (Piperaceae) was collected between the months of June and August (1993–1995), in sheltered areas of the ravine of Vicus, in the Department of Ancash, Province of Carhuaz, District of Marcará, Peru, at 3900 m altitude. I.D.F. conducted the botanical identification. A voucher specimen (IFV320) has been deposited at the Museo de Historia Natural Javier Prado of the Universidad Nacional Mayor de San Marcos in Lima, Perú.

Extraction and Isolation. Fresh *P. galioides* (whole plant, 5.6 kg) was crushed and macerated with ethanol at room temperature, yielding 72 g of crude extract after evaporation of the solvent (tensile strength⁸ activity: 36%, using 16 mg per mouse). The extract was partitioned between H₂O and CH₂-Cl₂, and the dichloromethane layer (20.4 g) was concentrated and further partitioned between hexane (6.2 g) and aqueous methanol 90% (12.6 g). An aliquot of the hexane fraction (1.90 g) was subjected to repeated purification using column and radial chromatography (eluent CH₂Cl₂). The following compounds were isolated and identified during the purification process: grifolin¹⁴ (140 mg), viridiflorol¹⁵ (5 mg), and the methyl ester of grifolic acid¹⁴ (38 mg). The subfraction with *R_f* between 0.4 and 0.5 (hexane/ethyl acetate, 85:15) was further chromatographed, using preparative HPLC (Si gel, hexane/*i*-PrOH, 95:5), to afford (+)-*epi*- α -bisabolol **2** (18 mg) (tensile strength⁸ activity: 62% using 4 mg per mouse).

(+)-*epi*- α -Bisabolol (**1**): colorless oil, [α]_D²³ +43.95° (*c* 0.38, CHCl₃) (lit.¹⁰ [α]_D²³ +45.3°); HRMS *m/z* 204.18737 (M⁺ – H₂O, deviation: –2.12 ppm); and exhibited spectral data (¹H NMR, ¹³C NMR; EIMS) values comparable to literature data.^{10–13,19}

Biological Assays. The methods used to determine the in vivo wound-healing activity^{3,8} and cytotoxicity^{5b,c} have been reported.

Acknowledgment. The authors gratefully acknowledge the financial assistance of the National Institutes of Health (Grant R15 CA 56911-01A1 to G.B.H.), Galenica Pharmaceuticals, Inc. (Grant SRA-1996 to A.J.V.), and the Program in Science and Technology Cooperation, Office of the Science Advisor, United States Agency for International Development (Grant No. 936-5542-G-00-918-00 to A.J.V.). The participation of Matthew Allan and Rosa Torres during the early stages of the investigation is recognized with gratitude.

References and Notes

- Antoniades, H. N. *Diabetes Rev.* **1995**, *3*, 129–138.
- Antoniades, H. N., Ed.; *Linking Cellular Injury to Gene Expression and Human Proliferative Disorders: Example with PDGF Genes*; Wiley-Liss, Inc.: New York, 1992; Vol. 6.
- Vaisberg, A. J.; Milla, M.; Planas, M. C.; Córdova, J. L.; de Agusti, E. R.; Ferreyra, R.; Mústiga, M. C.; Carlin, L.; Hammond, G. B. *Planta Med.* **1989**, *55*, 140–143.
- Our results were later corroborated by: Porras-Reyes, B. H.; Lewis, W. H.; Roman, J.; Simchowitz, L.; Mustoe, T. A. *Proc. Soc. Exptl. Biol. Med.* **1993**, *203*, 18–25.
- (a) Carlin, L.; Vaisberg, A. J.; Hammond, G. B. *Planta Med.* **1996**, *62*, 90–91. (b) Lee, K. K.; Zhou, B.-N.; Kingston, D. G. I.; Vaisberg, A. J.; Hammond, G. B. *Planta Med.* **1999**, *65*, 759–760. (c) Neto, C. C.; Vaisberg, A. J.; Zhou, B.-N.; Kingston, D. G. I.; Hammond, G. B. *Planta Med.* **2000**, *66*, 483–484.
- Selected references include: (a) Desmachelier, C.; Schaus, F. W.; Coussio, J.; Cicca, G. *J. Ethnopharmacol.* **1997**, *58*, 103–108. (b) Itokawa, H.; Ichihara, Y.; Mochizuki, M.; Enomori, T.; Morita, H.; Shirota, O.; Inamatsu, M.; Takeya, K. *Chem. Pharm. Bull.* **1991**, *39*, 1041–1042. (c) Chen, Z.-P.; Cai, Y.; Phillipson, J. D. *Planta Med.* **1994**, *60*, 541–545. (d) Pieters, L.; De Bruyne, T.; Claeys, M.; Vlietinck, A.; Calomme, M.; Vanden Berghe, D. *J. Nat. Prod.* **1993**, *56*, 899–906. (e) Pieters, L.; Bruyne, T. D.; Poel, B. V.; Vingerhoets, R.; Totte, J.; Berghe, D. V.; Vlietinck, A. *Phytomedicine* **1995**, *2*, 17–22. (f) Piacente, S.; Belisario, M. A.; Del Castillo, H.; Pizzi, C.; De Feo, V. *J. Nat. Prod.* **1998**, *61*, 318–322.
- Hammond, G. B.; Fernández, I. D.; Villegas, L. F.; Vaisberg, A. J. *J. Ethnopharmacol.* **1998**, *61*, 17–30.
- Hammond, G. B.; Vaisberg, A. J.; Fernández, I. D.; Maldonado, H.; Villegas, L. F.; Zavaleta, A. *J. Ethnopharmacol.* **1997**, *55*, 193–200.

- (9) Mahiou, V.; Roblot, F.; Hocquemiller, R.; Cavé, A.; De Arias, A. R.; Inchausti, A.; Yaluff, G.; Fournet, A. *J. Nat. Prod.* **1996**, *59*, 694–697.
- (10) Babin, D.; Fourneron, J.-D.; Julia, M. *Tetrahedron* **1981**, *37*, 1–7.
- (11) Hashidoko, Y.; Tahara, S.; Mizutani, J. *Phytochemistry* **1994**, *35*, 325–329.
- (12) O'Donnell, G. W.; Sutherland, M. D. *Aust. J. Chem.* **1989**, *42*, 2021–2034.
- (13) Carman, R.; Duffield, A. R. *Aust. J. Chem.* **1989**, *42*, 2035–2039.
- (14) Mahiou, V.; Roblot, F.; Hocquemiller, R.; Cavé, A.; Barrios, A. A.; Founet, A.; Ducrot, P. H. *J. Nat. Prod.* **1995**, *58*, 324–328.
- (15) San Feliciano, A.; Medarde, M.; Gordaliza, M.; del Olmo, E.; del Corral, J. M. *Phytochemistry* **1989**, *28*, 2717–2721.
- (16) Isaac, O. *Planta Med.* **1979**, *35*, 118–124.
- (17) Taspine is nontoxic to human foreskin fibroblasts at concentrations below 150 ng/mL.³ Its IC₅₀ was found to be 0.39 µg/mL against KB cells and 0.17 µg/mL against V-79 cells.^{6b}
- (18) Kelly, T. R.; Xie, L. X. *J. Org. Chem.* **1998**, *63*, 8045–8048.
- (19) (a) Nemoto, H.; Shiraki, M.; Nagamochi, M.; Fukumoto, K. *Tetrahedron Lett.* **1993**, *34*, 4939–4942. (b) Chen, X.-J.; Archelas, A.; Furstoss, R. *J. Org. Chem.* **1993**, *58*, 5528–5532.
- (20) Perhaps the higher ED₅₀ and GI₅₀ values found in **2** and **3** might be indirectly related to the fact that racemic mixtures of each were used in wound-healing and cytotoxicity experiments.

NP0102859